

# Study Companion: Answers to Clinicians' Questions About Biosimilar Use in Inflammatory Conditions



## Patient Resources

FDA Patient resources. Biosimilar basics for patients. <https://www.fda.gov/drugs/biosimilars/patient-materials>. Accessed May 5, 2022.

FDA. Biosimilar basics. <https://www.fda.gov/media/130918/download>. Accessed May 5, 2022.

FDA. What is a biosimilar? <https://www.fda.gov/media/108905/download>. Accessed May 5, 2022.

## Clinician Resources

American College of Rheumatology. Position statement: Biosimilars. <https://www.rheumatology.org/Portals/0/Files/Biosimilars-Position-Statement.pdf>. Published 2015. Accessed May 5, 2022.

American College of Rheumatology. Position statement: Pharmacovigilance. <https://www.rheumatology.org/Portals/0/Files/Pharmacovigilance-Position-Statement.pdf>. Published 2018. Accessed May 5, 2022.

American Gastroenterological Association. Biosimilars. <https://gastro.org/practice-resources/practice-tools/biosimilars/> Published 2022. Accessed May 6, 2022.

American Pharmacists Association. Biologics and biosimilar drug products: Pharmacist guide to patients' frequently asked questions. <https://www.pharmacist.com/Advocacy/Issues/Biosimilars/Biologics-and-Biosimilar-Drug-Products-Pharmacist-Guide-to-Patients-Frequently-Asked-Questions> Published 2022. Accessed May 6, 2022.

[Bhat S, Limdi JK, Cross RK, Farraye FA. Does similarity breed contempt? A review of the use of biosimilars in inflammatory bowel disease. \*Digestive Dis and Sci.\* 2021;66:2513-2352.](#)

[Blandizzi C, Meroni PL, Lapadula G. Comparing originator biologics and biosimilars: a review of the relevant issues. \*Clin Ther.\* 2017;39:1026-1039.](#)

Cardinal Health. State laws for biosimilar interchangeability. <https://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/state-regulations-for-biosimilar.html>. Accessed May 5, 2022.

Crohn's & Colitis Foundation. <https://www.crohnscolitisfoundation.org/science-and-professionals/education-resources/whitepapers/biosimilars> Published 2022. Accessed May 6, 2022.

FDA. Health care provider materials. <https://www.fda.gov/drugs/biosimilars/health-care-provider-materials>. Accessed May 5, 2022.

FDA. Overview of biosimilar products. <https://www.fda.gov/media/151058/download>. Accessed May 5, 2022.

FDA. Biosimilar product regulatory review and approval. <https://www.fda.gov/files/drugs/published/Biosimilar-Product-Regulatory-Review-and-Approval.pdf>. Accessed May 5, 2022.

FDA. Biosimilar regulatory review and approval. <https://www.fda.gov/media/151061/download>. Accessed May 5, 2022.

## **Study Companion: Answers to Clinicians' Questions About Biosimilar Use in Inflammatory Conditions**



FDA. Interchangeable biological products. <https://www.fda.gov/media/151094/download>. Accessed May 5, 2022.

FDA. Prescribing biosimilar products. <https://www.fda.gov/media/108103/download>. Accessed May 5, 2022.

FDA. Biological product definitions. <https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf>. Accessed May 5, 2022.

National Psoriasis Foundation. Biosimilars. <https://www.psoriasis.org/biosimilars/> Published 2022. Accessed May 6, 2022.